BBIO BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $10.1M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Kumar Neil 3 fills | Chief Executive Officer | Sell 10b5-1 | 10,000 | $84.03 | $840.3K | 507,586 −1.9% of holding | |
| Kumar Neil 4 fills | Chief Executive Officer | Sell 10b5-1 | 34,980 | $82.53 | $2.9M | 276,407 −11.2% of holding | |
| Apuli Maricel | Chief Accounting Officer | Sell 10b5-1 | 2,000 | $80.06 | $160.1K | 127,401 −1.5% of holding | |
| Cook Jennifer E. 2 fills | Director | Sell 10b5-1 | 148,589 | $88.54 | $13.2M | 120,805 −55.2% of holding | |
| Ellis Andrea | Director | Sell 10b5-1 | 17,167 | $84.00 | $1.4M | 22,579 −43.2% of holding | |
| Cook Jennifer E. | Director | Sell 10b5-1 | 37,167 | $70.00 | $2.6M | 8,383 −81.6% of holding | |
| Cook Jennifer E. | Director | Sell 10b5-1 | 2,196 | $68.57 | $150.6K | 8,383 −20.8% of holding | |
| Valantine Hannah | Director | Sell 10b5-1 | 2,196 | $68.57 | $150.6K | 9,259 −19.2% of holding | |
| Valantine Hannah | Director | Sell 10b5-1 | 2,808 | $68.00 | $190.9K | 11,455 −19.7% of holding | |
| Cook Jennifer E. 2 fills | Director | Sell 10b5-1 | 90,240 | $66.62 | $6.0M | 8,092 −91.8% of holding | |
| Kumar Neil 6 fills | Chief Executive Officer | Sell 10b5-1 | 40,000 | $67.88 | $2.7M | 4,331,299 −0.9% of holding | |
| Kumar Neil 8 fills | Chief Executive Officer | Sell 10b5-1 | 40,000 | $67.46 | $2.7M | 4,356,247 −0.9% of holding | |
| Kumar Neil 5 fills | Chief Executive Officer | Sell 10b5-1 | 26,103 | $69.44 | $1.8M | 267,174 −8.9% of holding | |
| Trimarchi Thomas 2 fills | President and CFO | Sell 10b5-1 | 13,651 | $65.08 | $888.4K | 362,389 −3.6% of holding | |
| Scott Randal W. 4 fills | Director | Sell 10b5-1 | 10,000 | $67.15 | $671.5K | 15,389 −39.4% of holding | |
| Kumar Neil 6 fills | Chief Executive Officer | Sell 10b5-1 | 40,000 | $66.91 | $2.7M | 4,364,473 −0.9% of holding | |
| Kumar Neil 6 fills | Chief Executive Officer | Sell 10b5-1 | 40,000 | $67.90 | $2.7M | 4,387,230 −0.9% of holding | |
| Apuli Maricel | Chief Accounting Officer | Sell 10b5-1 | 2,000 | $71.58 | $143.2K | 134,115 −1.5% of holding | |
| Kumar Neil 2 fills | Chief Executive Officer | Sell 10b5-1 | 40,000 | $74.60 | $3.0M | 4,398,447 −0.9% of holding | |
| Kumar Neil 6 fills | Chief Executive Officer | Sell 10b5-1 | 40,000 | $74.62 | $3.0M | 4,431,375 −0.9% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.